Clinical trials: Cardiovascular Disease Other, active
Opioid-induced Constipation
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
The research objective is to characterize the risk of a major adverse cardiovascular event (MACE) among new users of naldemedine versus new users of lubiprostone and new users of naloxegol as comparator opioid induced…
- Trial name
- NCT03720613
- Testing
- Naldemedine, Lubiprostone, Naloxegol
- Where
- United States
- Volunteers
- 34,532 people
- Sponsor
- BioDelivery Sciences International
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
This phase II MATCH treatment trial identifies the effects of crizotinib in patients whose cancer has a genetic change called ALK rearrangement.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439266
- Testing
- Crizotinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Mild Cognitive Disorder, Alzheimer Disease
Digital Dementia Registry Bavaria (digiDEM Bayern): a Multicentre, Prospective, Longitudinal Register Study Including People With Mild Cognitive Impairment and Dementia as Well as Their Family Caregivers
Around 57 million people worldwide live with dementia, with approximately 10 million new cases diagnosed each year. By the end of 2023, around 1.8 million people were living with dementia in Germany, the majority of whom were…
- Conditions
- Mild Cognitive Disorder, Alzheimer Disease, Vascular Dementia, Dementia in Other Diseases Classified Elsewhere
- Trial name
- digiDEM Bayern (NCT07721701)
- Where
- 12 sites in Germany
- Volunteers
- 5,000 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Valvular Heart Disease, Pericardial Disease
PPG to Predict Ejection Fraction and Other Echographic Data in the General Population
The investigators are aiming to investigate the association between ejection fraction (EF) determined by echocardiography and signals obtained from Photoplethysmography (PPG) in the general population.
- Conditions
- Valvular Heart Disease, Pericardial Disease, Cardiomyopathies
- Trial name
- NCT04843371
- Testing
- Photoplethysmography
- Where
- 3 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tulane University
Brain Injuries, Traumatic, Brain Injuries, Acute
Critical Hyperacute Assessment Research On Neurobiomarker Kinetics in Acute Brain Injury
Traumatic brain injury (TBI) and other conditions that reduce blood flow to the brain - such as cardiac arrest (CA) - are life-threatening medical emergencies.
- Conditions
- Brain Injuries, Traumatic, Brain Injuries, Acute, Hypoxia, Brain, Cardiac Arrest (CA)
- Trial name
- CHARON (NCT07782216)
- Where
- 4 sites in Hungary
- Volunteers
- 477 people
- Sponsor
- University of Pecs
Multiple Myeloma
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab…
- Trial name
- MAGNETISMM-5 (NCT05020236)
- Testing
- Elranatamab, Daratumumab, Pomalidomide
- Where
- 237 sites in United States, Argentina and 24 more
- Volunteers
- 893 people
- Sponsor
- Pfizer
Inflammation Biomarkers, Heart Failure
Descriptive Study of Circulating Gene or Protein Inflammatory Biomarkers and Bioimpedance Parameters in a Population of Patients Hospitalized for Decompensated Heart Failure With Preserved or Mildly Reduced Cardiac Function
The goal of this observational study is to determine whether changes in the inflammatory profile of heart failure patients can help identify those who may have a worse prognosis or who might benefit more from specific treatments.
- Trial name
- BIOFEVIP (NCT07320014)
- Testing
- Inflammatory biomarker sample collection
- Where
- Spain
- Volunteers
- 112 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma or MDS. Non-chemotherapeutic interventions such as physical activity and nutritional interventions (e.g.…
- Conditions
- Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
- Trial name
- NCT05312255
- Testing
- Behavioral Intervention, Beta-Adrenergic Antagonist, Propranolol
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Roswell Park Cancer Institute
Hypertension (HTN), Obesity &Amp; Overweight
Mediterranean-DASH Intervention for Neurodegenerative Delay and High-Intensity Interval Training in Adults With Hypertension
This pilot study examines whether a 4-week diet and exercise intervention can improve blood pressure, heart health, and sleep in physically inactive individuals with high blood pressure and overweight or obesity.
- Conditions
- Hypertension (HTN), Obesity &Amp; Overweight, Sedentary
- Trial name
- MIND HIIT (NCT07130539)
- Testing
- MIND HIIT
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Texas Woman's University
Psychotic Disorders
Improving Heart and Metabolic Health in People With Severe Mental Illness Through a Long-term Clinical Trial
Background Cardiometabolic conditions-including cardiovascular disease, type 2 diabetes, and obesity-are highly prevalent among individuals with psychotic disorders.
- Trial name
- LAGOM (NCT06781801)
- Testing
- Intervention
- Where
- 6 sites in Sweden
- Volunteers
- 650 people
- Sponsor
- Vastra Gotaland Region
Multiple Myeloma and Other Plasma Cell Neoplasms
Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
This study is a 2-part study with a dose-escalation part and a dose-expansion part. The aim of the dose-escalation part is to determine the maximum tolerated dose (MTD) and/or establish the recommended Phase 2 dose (RP2D) in the…
- Trial name
- NCT07529782
- Testing
- HDP-101
- Where
- 5 sites in China
- Volunteers
- 15 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Relapsed or Refractory Multiple Myeloma, Hematological Malignancy
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
This is a Phase 1a/1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG301 in Patients with Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
- Trial name
- NCT04684108
- Testing
- SG301
- Where
- 14 sites in China
- Volunteers
- 61 people
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
Type 2 Diabetes
A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China
The study is testing the incidence of MACE and incidence of renal events between Ozempic® users and users with other anti-diabetic medications in T2D patients.
- Trial name
- SPOTLIGHT (NCT07456774)
- Where
- China
- Volunteers
- 100,000 people
- Sponsor
- Novo Nordisk A/S
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
This phase II MATCH treatment trial identifies the effects of crizotinib in patients whose cancer has a genetic change called ROS1 translocation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439253
- Testing
- Crizotinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00544115
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Volunteers
- 260 people
- Sponsor
- City of Hope Medical Center
Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder
Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)
This is a research protocol that will examine Hematopoietic Stem Cell Transplantation (HSCT) using a reduced conditioning regimen (RIC) with total body Irradiation (TBI) in those diagnosed with Common Variable Immunodeficiency…
- Conditions
- Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder, Immune Dysregulation, DiGeorge Syndrome
- Trial name
- CVID/PIRD (NCT07284641)
- Testing
- Hematopoietic stem cell transplant (HSCT)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Paul Szabolcs
Hypertension (HTN)
Clinical Trial in Hypertensive Patients Comparing Two Cardiorespiratory Exercise Protocols, Low-volume Sprint Interval Training (SIT) Versus Moderate-intensity Continuous Training (MICT), to Evaluate Decreases in Ambulatory Blood Pressure and Other Clinical Variables.
This randomized clinical trial aims to compare two cardiorespiratory exercise training protocols - Sprint Interval Training (SIT), characterized by short, maximal-intensity efforts, versus Moderate-Intensity Continuous Training…
- Trial name
- NCT07229196
- Testing
- SIT group: 2-4 maximal 20-30-second cycling sprints (≥100% VO₂max) with recovery intervals (2-4 min), total duration ≤15 minutes per session., MICT group: Continuous cycling at 50-70% of VO₂max, 15-30 minutes per session.
- Where
- Argentina
- Volunteers
- 20 people
- Sponsor
- Unidad Enfermedades Cardiometabolicas- Hospital Interzonal General Agudos San Martin de La Plata
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
HCM, Noonan Syndrome and Other Rasopathy
Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERIT
This project seeks to perform a Phase 3 clinical trial to test whether an FDA-approved cancer drug called trametinib is effective in treating young infants with genetic conditions called RASopathies and a severe, life-threatening…
- Conditions
- HCM, Noonan Syndrome and Other Rasopathy, Heart Failure (Pediatric)
- Trial name
- Baby MERIT (NCT07817186)
- Testing
- Trametinib
- Volunteers
- 25 people
- Sponsor
- Carelon Research
Coronary Atherosclerosis and Other Heart Disease, Cardiovascular Diseases
The DANE-HEART Trial - Computed Tomography Coronary Angiography for Primary Prevention
The goal of this randomized controlled clinical trial in asymptomatic individuals with risk factors for cardiovascular disease is to investigate whether a preventive treatment strategy guided by computed tomography coronary…
- Trial name
- NCT05677386
- Testing
- Primary preventive treatment guided by CTCA, Cardiovascular risk Score
- Where
- 2 sites in Denmark
- Volunteers
- 6,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet